Table 2.
Cohort 1: GI irAE characteristics in patients with ircAEs.
| Variable | Developed Only ircAEs | Developed ircAEs + GI irAEs | p-Value | |||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| All Patients with ircAE | 126 | 82.9 | 26 | 17.1 | ||
| ircAE Phenotype | Bullous | 4 | 80.0 | 1 | 20.0 | p = 0.768 |
| Eczema | 6 | 100.0 | 0 | 0.0 | ||
| Lichenoid | 2 | 100.0 | 0 | 0.0 | ||
| Maculopapular | 26 | 83.9 | 5 | 16.1 | ||
| Pruritus | 64 | 79.0 | 17 | 21.0 | ||
| Psoriasis | 5 | 100.0 | 0 | 0.0 | ||
| Urticaria | 10 | 90.9 | 1 | 9.1 | ||
| Vitiligo | 9 | 81.8 | 2 | 18.2 | ||
| ircAE Grade | 1 | 76 | 81.7 | 17 | 18.3 | p = 0.106 |
| 2 | 43 | 89.6 | 5 | 10.4 | ||
| 3 | 7 | 63.6 | 4 | 36.4 | ||
| ICB Target | Anti-PD1/PDL1 | 96 | 84.2 | 18 | 15.8 | p = 0.456 |
| Anti-CTLA4 + Anti-PD1 | 30 | 79.0 | 8 | 21.1 | ||
| ICB Antibody | Atezolizumab | 9 | 81.8 | 2 | 18.2 | p = 0.121 |
| Avelumab | 4 | 50.0 | 4 | 50.0 | ||
| Durvalumab | 7 | 100.0 | 0 | 0.0 | ||
| Nivolumab | 26 | 86.7 | 4 | 13.3 | ||
| Pembrolizumab | 50 | 86.2 | 8 | 13.8 | ||
| Ipilimumab/ Nivolumab | 30 | 79.0 | 8 | 21.1 | ||
| Best Response to ICB | Complete Response | 7 | 77.8 | 2 | 22.2 | p = 0.880 |
| Partial Response | 30 | 85.7 | 5 | 14.3 | ||
| POD | 29 | 85.3 | 5 | 14.7 | ||
| Stable | 60 | 81.1 | 14 | 18.9 | ||
| Patients with Both irColitis and ircAE | n | % | p-value | |||
| GI irAE Grade | 1 | 15 | 57.7 | - | ||
| 2 | 9 | 34.6 | ||||
| 3 | 2 | 7.7 | ||||
| Relationship to ircAE | GI irAE Before ircAE | 8 | 30.8 | p = 0.014 | ||
| GI irAE After ircAE | 18 | 69.2 | ||||
p-values represent chi-squared tests between patients who developed only ircAEs and those who developed both ircAEs + GI irAEs. Binomial probability was assessed for ircAE preceding GI irAE using the Bernoulli model.